P3‐391: Statins for the treatment of dementia
The DOI matches its Crossref record.
Abstract
There is accumulating evidence that cholesterol may be implicated in the pathogenesis of dementia and this has led investigators to assess the possible role of lipid lowering agents in the treatment of dementia. This Cochrane review evaluated the efficacy of statins in the treatment of Alzheimer's disease (AD) and vascular dementia (VaD). Randomised double-blind placebo-controlled trials in which a statin was given for at least 6 months to patients with a diagnosis of AD or VaD were identified by a complete search of the Dementia and Cognitive Improvement Group Specialized Register, The Cochrane Library, MEDLINE, EMBASE, PsyclINFO, CINAHL and LILACS, trials databases and grey literature sources. Any type of statin (hydrophilic and lipophilic) given in appropriate dose compared to placebo was considered. Primary outcome measures were a change in MMSE and ADAS-Cog in patients with a diagnosis of AD/VaD on treatment with statins. 3 studies with 730 participants were identified - Simons 2002, ADCLT 2005, LEADe 2008. The 3 studies assessed change in ADAS-Cog from baseline in patients with AD. Mean change was entered into a meta-analysis; when the 3 studies were combined there was no significant difference in ADAS-Cog between the statin group and the placebo group [mean difference 0.18, 95% CI -1.11, 1.48, p = 0.78]. 2 studies assessed change in MMSE from baseline (Simons 2002, ADCLT 2005); there was a significant difference in MMSE between the statin group and the placebo group (favouring statins) when the two studies were combined [mean difference1.81, 95% CI 0.69, 2.98, p = 0.002]. There were no studies identified assessing changes in cognition in patients with VaD. There was no evidence that statins were detrimental to cognition. There is some evidence from the smaller trials (Simons 2002, ADCLT 2005) that statins may be beneficial in treatment of dementia but this is not borne out in the larger LEADe study. Further studies are required to be certain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
Cholesterol metabolism in Huntington disease
Karasinska, J. M., & Hayden, M. R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.132 · Cited by 154
Butterfield, D. A., Barone, E., & Mancuso, C. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.007 · Cited by 80
“However, although there was beneficial effect of statins on LDLcholesterol plasma levels, no beneficial effect on cognitive function was observed [77,85].”
Background
Metadata
- Authors
- McGuinness, B., O'Hare, J., Bullock, R., Malouf, R., Craig, D., & Passmore, P.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2010-07
- Volume
- 6
- Issue
- 4S_Part_18
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2604889046
- Cited by
- 40
- References
- 0
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: P3‐391: Statins for the treatment of dementia. https://app.cochat.ai/papers/10.1016/j.jalz.2010.05.1933
- The paper
- McGuinness, B., O'Hare, J., Bullock, R., Malouf, R., Craig, D., & Passmore, P. (2010). P3‐391: Statins for the treatment of dementia. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2010.05.1933
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.